TNFRSF18 and neoplasm: In mouse tumor models, the combined application of a GITR antibody and a CTLA‐4 antibody results in 80% tumor inhibition, reduction of intra‐tumoral Treg (via GITR), and stimulation of CD8+ T cells (via CTLA‐4) [18, 19].